# Jorien van der Schaft

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jorien-van-der-schaft/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,590 |
| Field | Dermatology and Skin Diseases |
| h-index | 19 |
| i10-index | 24 |
| Last Known Institution | University Medical Center Utrecht |
| OpenAlex ID | https://openalex.org/A5001775843 |
| Works | 40 |

## Researcher papers

- [When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council](https://scholariq.org/papers/when-does-atopic-dermatitis-warrant-systemic-therapy-recommendations-from-an/)
- [The association between vitamin D and cognition: A systematic review](https://scholariq.org/papers/the-association-between-vitamin-d-and-cognition-a-systematic-review/)
- [Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis](https://scholariq.org/papers/goblet-cell-scarcity-and-conjunctival-inflammation-during-treatment-with/)
- [Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry](https://scholariq.org/papers/dupilumab-is-very-effective-in-a-large-cohort-of-difficult-to-treat-adult-atopic/)
- [Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers](https://scholariq.org/papers/confirmation-of-multiple-endotypes-in-atopic-dermatitis-based-on-serum/)
- [Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry](https://scholariq.org/papers/dupilumab-shows-long-term-effectiveness-in-a-large-cohort-of-treatment/)
- [Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis](https://scholariq.org/papers/drug-survival-for-ciclosporin-a-in-a-long-term-daily-practice-cohort-of-adult/)
- [Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment](https://scholariq.org/papers/economic-burden-of-adult-patients-with-moderate-to-severe-atopic-dermatitis/)
- [Dupilumab facial redness: Positive effect of itraconazole](https://scholariq.org/papers/dupilumab-facial-redness-positive-effect-of-itraconazole/)
- [Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis](https://scholariq.org/papers/long-term-follow-up-and-treatment-outcomes-of-conjunctivitis-during-dupilumab/)

## Researcher topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Food Allergy and Anaphylaxis Research](https://scholariq.org/topics/food-allergy-and-anaphylaxis-research/)
- [Urticaria and Related Conditions](https://scholariq.org/topics/urticaria-and-related-conditions/)

## Researcher university

- [University Medical Center Utrecht](https://scholariq.org/institutions/university-medical-center-utrecht/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.